The denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and ...

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...

This is likely to limit J&J’s ability to seek damages from Pfizer, which has launched a biosimilar of Remicade ‘at risk’ in late 2016. Latest figures show that Remicade’s sales are ...

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...

The US Food and Drug Administration has approved Celltrion's biosimilar of Johnson & Johnson's Remicade (infliximab) - but the launch date of the blockbuster's cheaper rival remains uncertain.

The Global Remicade Biosimilars Market is expected to grow at 9.32% CAGR from 2025 to 2032. The latest Research report published by CMI with the title "An Increase in Demand and Opportunities for ...

Although more research is needed in pediatric patients, biosimilars could improve treatment access and reduce costs.

CT-P13, intravenous infliximab, developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar therapy and has been the most established biosimilar treatment in the Canadian ...